Container for liquid pharmaceutical compositions with high moistureproof properties
Abstract
FIELD: packing industry. SUBSTANCE: material of chamber walls comprises two layers. Internal layer is made of polyethylene or polypropylene film. Outer layer is made of polychlorotrifluoroethylene film. Layers are inseparably connected to each other. Container is transparent and is equipped with device, through which liquid may come out, when desired. EFFECT: produced container may be safely used to store solutions without reduction of preservatives content in them. 62 cl, 4 ex, 5 dwg
Term
Term ended
Expired 23 June 2024, 2.3 years ago.
- Priority
- Filed
- Granted
- Expired
- Today
62 claims: 6 independent, 56 dependent
- 1Гибкий, по меньшей мере частично прозрачный контейнер для хранения фармацевтического раствора, содержащего консервант, в водонепроницаемой камере, материал стенок которой содержит по меньшей мере два слоя, внутренний слой которой находится в непосредственном контакте с указанной жидкостью, когда камера содержит жидкость, и наружный слой которой не находится в контакте с указанной жидкостью, когда камера содержит жидкость, где указанные внутренний и наружный слои неразрывно соединены вместе, характеризующийся тем, что при заполнении камеры водой и ее хранении при температуре примерно 5°С в течение 24 месяцев, менее 10 мас.%, предпочтительно менее 5 мас.%, более предпочтительно менее 3 мас.% воды диффундирует из контейнера;и при заполнении камеры водой, содержащей примерно 1,8 мг/мл фенола и ее хранении при температуре примерно 5°С в течение 24 месяцев или ее хранении при температуре примерно 37°С в течение 12 недель, изменение концентрации фенола в жидкости составляет менее примерно 10 мас.%, предпочтительно менее 5 мас.%, более предпочтительно менее 3 мас.%, и при заполнении камеры водой, содержащей примерно 2,06 мг/мл метакрезола, и хранении при температуре примерно 5°С в течение 24 месяцев или хранении при температуре примерно 37°С в течение 12 недель, изменение концентрации метакрезола составляет менее примерно 10 мас.%, предпочтительно менее примерно 5 мас.%, более предпочтительно менее примерно 2 мас.%.
- 2Контейнер по п.1, в котором толщина внутреннего слоя составляет более примерно 10 мкм, предпочтительно более примерно 20 мкм, и менее примерно 60 мкм, предпочтительно менее примерно 50 мкм, более предпочтительно менее примерно 40 мкм.
- 3Контейнер по п.1, из которого при наполнении водой и при хранении при температуре примерно 5°С в течение 24 месяцев диффундирует менее 10 мас.%, предпочтительно менее 5 мас.%, более предпочтительно менее 2 мас.% воды.
- 4Контейнер по п.1, где наружный слой камеры контейнера выполнен таким образом, что он обеспечивает соблюдение требования, когда при заполнении камеры водой и ее хранении при температуре примерно 5°С в течение 24 месяцев, менее 10 мас.%, предпочтительно менее 5 мас.%, более предпочтительно менее 3 мас.% воды диффундирует из контейнера.
- 5Контейнер по п.1, где внутренний слой камеры контейнера выполнен таким образом, что он обеспечивает соблюдение требования, когда при заполнении камеры водой, содержащей примерно 1,8 мг/мл фенола, и ее хранении при температуре примерно 5°С в течение 24 месяцев, изменение концентрации фенола в жидкости составляет менее примерно 10 мас.%, предпочтительно менее 5 мас.%, более предпочтительно менее 3 мас.%;или когда при заполнении камеры водой, содержащей примерно 1,8 мг/мл фенола, и ее хранении при температуре примерно 37°С в течение 12 недель, изменение концентрации фенола в жидкости составляет менее примерно 10 мас.%, предпочтительно менее 5 мас.%, более предпочтительно менее 3 мас.%.
- 6Контейнер по п.1, где внутренний слой является свариваемым.
- 7Контейнер по п.1, отличающийся тем, что изготовлен из пакетной полимерной пленки, которая при тестировании тестом А, описанным выше, дает максимальную потерю метакрезола примерно 10 мас.%, предпочтительно не более примерно 5 мас.%.
- 8Контейнер п.1, который изготовлен из пакетной полимерной пленки, которая при тестировании тестом А, описанным выше, дает изменение значения рН не более примерно +/- 0,2.
- 9Контейнер по п.1, который изготовлен из пакетной полимерной пленки, которая при тестировании тестом В, описанным выше, дает максимальную потерю массы примерно 2,5 мас.%, предпочтительно не более примерно 1 мас.%.
- 10Контейнер по п.1, который изготовлен из пакетной полимерной пленки, которая при тестировании тестом В, описанным выше, дает максимальную потерю метакрезола примерно 10 мас.%, предпочтительно не более примерно 5 мас.%.
- 11Контейнер по п.1, который изготовлен из пакетной полимерной пленки, которая при тестировании тестом В, описанным выше, дает изменение значения рН не более примерно +/- 0,2.
- 12Контейнер по п.1, который изготовлен из пакетной полимерной пленки, которая при тестировании тестом С, описанным выше, дает максимальную потерю массы примерно 2,5 мас.%, предпочтительно не более примерно 1 мас.%.
- 13Контейнер по п.1, который изготовлен из пакетной полимерной пленки, которая при тестировании тестом С, описанным выше, дает максимальную потерю метакрезола примерно 10 мас.%, предпочтительно не более примерно 5 мас.%.
- 14Контейнер по п.1, который изготовлен из пакетной полимерной пленки, которая при тестировании тестом С, описанным выше, дает максимальную потерю фенола примерно 10 мас.%, предпочтительно не более чем примерно 5 мас.%.
- 15Контейнер по п.1, который изготовлен из пакетной полимерной пленки, которая при тестировании тестом С, описанным выше, дает изменение значения рН не более чем примерно +/- 0,2.
- 16Контейнер по п.1, который изготовлен из пакетной полимерной пленки, которая удовлетворяет тесту D, описанному выше, для разведения 1:50, предпочтительно для разведения 1:100, более предпочтительно для разведения 1:200, наиболее предпочтительно для разведения 1:400.
- 17Контейнер по п.1, в котором толщина связующего слоя или связующих слоев в полимерной пленке находится в интервале от примерно 1 мкм до примерно 10 мкм, предпочтительно менее примерно 8 мкм, более предпочтительно менее примерно 6 мкм.
- 18Контейнер по п.1, отличающийся тем, что оснащен устройством, посредством которого из него можно выталкивать жидкость.
- 19Контейнер по п.1, отличающийся тем, что содержит дополнительный третий полимерный слой с внешней стороны полихлортрифторэтиленового слоя.
- 20Контейнер по п.1, отличающийся тем, что когда он полностью заполнен жидкостью, может содержать по меньшей мере примерно 0,5 мл жидкости, предпочтительно по меньшей мере примерно 1 мл жидкости, и не более примерно 10 мл жидкости, предпочтительно не более примерно 5 мл жидкости, более предпочтительно не более примерно 2 мл жидкости, и предпочтительно объем жидкости составляет примерно 1,5 мл.
- 21Контейнер по п.1, отличающийся тем, что когда он полностью заполнен жидкостью, может содержать от примерно 2 мл до примерно 4 мл жидкости, предпочтительно примерно 3 мл жидкости.
- 22Контейнер по п.1, частично или полностью наполненный жидкой фармацевтической композицией.
- 23Контейнер по п.22, в котором содержащаяся жидкая фармацевтическая композиция занимает по меньшей мере 95 об.%, предпочтительно по меньшей мере 98 об.%, более предпочтительно по меньшей мере 99 об.% и наиболее предпочтительно по меньшей мере 99,9 об.% внутренней части контейнера.
- 24Контейнер по п.1, частично или полностью наполненный жидкой фармацевтической композицией, где активный ингредиент представляет собой пептид.
- 25Контейнер по п.24, где пептид представляет собой инсулин.
- 26Контейнер по п.25, где содержание инсулина находится в интервале от примерно 10 U/мл до примерно 1500 U/мл.
- 27Контейнер по п.1, содержащий консервант.
- 28Контейнер по п.1, частично или полностью наполненный жидкой фармацевтической композицией, содержащей фенол.
- 29Контейнер по п.1, частично или полностью наполненный жидкой фармацевтической композицией, содержащей метакрезол.
- 30Контейнер по п.1, частично или полностью наполненный жидкой фармацевтической композицией, содержащей бензиловый спирт.
- 31Контейнер для хранения фармацевтического раствора, содержащего консервант, в водонепроницаемой камере, материал стенок которой содержит по меньшей мере два слоя, внутренний слой которой находится в непосредственном контакте с указанной жидкостью, когда камера содержит жидкость, а другой слой, состоящий из полихлортрифторэтиленовой пленки, которая не находится в контакте с указанной жидкостью, когда камера содержит жидкость, где указанный внутренний слой состоит из полиэтиленовой или полипропиленовой пленки, и либо указанный внутренний слой и указанный полихлортрифторэтиленовый слой представляют собой соэкструдат или экструдат-ламинат, либо указанный внутренний слой и указанный полихлотрифторэтиленовый слой соединены вместе, и толщина полихлортрифторэтиленового слоя составляет более примерно 40 мкм и менее примерно 100 мкм, предпочтительно менее примерно 75 мкм.
- 32Контейнер по п.31, отличающийся тем, что является по меньшей мере частично прозрачный.
- 33Контейнер по п.31, отличающийся тем, что является полностью прозрачным.
- 34Контейнер по п.1, отличающийся тем, что изготовлен из пакетной полимерной пленки, которая при тестировании тестом А, описанным выше, дает максимальную потерю метакрезола примерно 10 мас.%, предпочтительно не более примерно 5 мас.%.
- 35Контейнер п.31, который изготовлен из пакетной полимерной пленки, которая при тестировании тестом А, описанным выше, дает изменение значения рН не более примерно +/- 0,2.
- 36Контейнер по п.31, который изготовлен из пакетной полимерной пленки, которая при тестировании тестом В, описанным выше, дает максимальную потерю массы примерно 2,5 мас.%, предпочтительно не более примерно 1 мас.%.
- 37Контейнер по п.31, который изготовлен из пакетной полимерной пленки, которая при тестировании тестом В, описанным выше, дает максимальную потерю метакрезола примерно 10 мас.%, предпочтительно не более примерно 5 мас.%.
- 38Контейнер по п.31, который изготовлен из пакетной полимерной пленки, которая при тестировании тестом В, описанным выше, дает изменение значения рН не более примерно +/- 0,2.
- 39Контейнер по п.31, который изготовлен из пакетной полимерной пленки, которая при тестировании тестом С, описанным выше, дает максимальную потерю массы примерно 2,5 мас.%, предпочтительно не более примерно 1 мас.%.
- 40Контейнер по п.31, который изготовлен из пакетной полимерной пленки, которая при тестировании тестом С, описанным выше, дает максимальную потерю метакрезола примерно 10 мас.%, предпочтительно не более примерно 5 мас.%.
- 41Контейнер по п.31, который изготовлен из пакетной полимерной пленки, которая при тестировании тестом С, описанным выше, дает максимальную потерю фенола примерно 10 мас.%, предпочтительно не более чем примерно 5 мас.%.
- 42Контейнер по п.31, который изготовлен из пакетной полимерной пленки, которая при тестировании тестом С, описанным выше, дает изменение значения рН не более чем примерно +/- 0,2.
- 43Контейнер по п.31, который изготовлен из пакетной полимерной пленки, которая удовлетворяет тесту D, описанному выше, для разведения 1:50, предпочтительно для разведения 1:100, более предпочтительно для разведения 1:200, наиболее предпочтительно для разведения 1:400.
- 44Контейнер по п.31, в котором толщина связующего слоя или связующих слоев в полимерной пленке находится в интервале от примерно 1 мкм до примерно 10 мкм, предпочтительно менее примерно 8 мкм, более предпочтительно менее примерно 6 мкм.
- 45Контейнер по п.31, отличающийся тем, что он является гибким.
- 46Контейнер по п.31, отличающийся тем, что оснащен устройством, посредством которого из него можно выталкивать жидкость.
- 47Контейнер по п.31, отличающийся тем, что содержит дополнительный третий полимерный слой с внешней стороны полихлортрифторэтиленового слоя.
- 48Контейнер по п.31, отличающийся тем, что когда он полностью заполнен жидкостью, может содержать по меньшей мере примерно 0,5 мл жидкости, предпочтительно по меньшей мере примерно 1 мл жидкости, и не более примерно 10 мл жидкости, предпочтительно не более примерно 5 мл жидкости, более предпочтительно не более примерно 2 мл жидкости, и предпочтительно объем жидкости составляет примерно 1,5 мл.
- 49Контейнер по п.31, отличающийся тем, что когда он полностью заполнен жидкостью, может содержать от примерно 2 мл до примерно 4 мл жидкости, предпочтительно примерно 3 мл жидкости.
- 50Контейнер по п.31, частично или полностью наполненный жидкой фармацевтической композицией.
- 51Контейнер по п.31, в котором содержащаяся жидкая фармацевтическая композиция занимает по меньшей мере 95 об.%, предпочтительно по меньшей мере 98 об.%, более предпочтительно по меньшей мере 99 об.% и наиболее предпочтительно по меньшей мере 99,9 об.% внутренней части контейнера.
- 52Контейнер по п.31, частично или полностью наполненный жидкой фармацевтической композицией, где активный ингредиент представляет собой пептид.
- 53Контейнер по п.52, где пептид представляет собой инсулин.
- 54Контейнер по п.53, где содержание инсулина находится в интервале от примерно 10 U/мл до примерно 1500 U/мл.
- 55Контейнер по п.31, содержащий консервант.
- 56Контейнер по п.31, частично или полностью наполненный жидкой фармацевтической композицией, содержащей фенол.
- 57Контейнер по п.31, частично или полностью наполненный жидкой фармацевтической композицией, содержащей метакрезол.
- 58Контейнер по п.31, частично или полностью наполненный жидкой фармацевтической композицией, содержащей бензиловый спирт.
- 59Контейнер по п.31, в котором при заполнении его водой, содержащей примерно 2,06 мг/мл метакрезола, и хранении при температуре примерно 5°С в течение 24 месяцев, изменение концентрации метакрезола составляет менее примерно 10 мас.%, предпочтительно менее примерно 5 мас.%, более предпочтительно менее примерно 2 мас.%.
- 60Контейнер по п.31, в котором при заполнении его водой, содержащей примерно 2,06 мг/мл метакрезола, и хранении при температуре примерно 37°С в течение 12 недель, изменение концентрации метакрезола составляет менее примерно 10 мас.%, предпочтительно менее примерно 5 мас.%, более предпочтительно менее примерно 2 мас.%.
- 61Применение контейнера по любому из пп.1-60 для хранения жидкой фармацевтической композиции, упомянутой в любом из предшествующих пунктов.
- 62Материал пленки, содержащей по меньшей мере два слоя, где указанные слои неразрывно соединены вместе, который можно использовать для изготовления прозрачного контейнера по любому из пп.1-60.
Independent claims62
145 paragraphs in 10 sections, as filed
TECHNICAL FIELD
The present invention relates to a transparent plastic container which can be used for storage of liquid solutions or suspensions, such as drugs that can contain preservatives.
BACKGROUND
Some medications are delivered to patients in a solid form, other in liquid form. Frequently, liquid medications are delivered in a container. Some containers consist wholly or mainly of glass, other containers consist wholly or mainly of other materials such as plastic. Medication in solid form are often sold in a glass container or a plastic container. An example of the plastic container is a blister pack.
The pharmaceutical composition in liquid form, the active ingredient is in dissolved or suspended form. In addition to the active ingredient, the pharmaceutical composition may comprise a pharmaceutically active carrier, a disintegrator, a stabilizer, or a buffering agent.
For administration of various drugs used different routes of administration. Some drugs are administered by the oral route, other are administered by injection, e.g., intravenous or subcutaneous. Many drugs are peptides, such as insulin, administered by injection. Previously used syringes for injections. Now it is becoming more common for insulin use so-called injection system such as a pencil. Furthermore, the use of pumps for injection may become a popular way of administration of drugs by injection. In certain Pompe aqueous formulation will be presented in a glass reservoir or another hard reservoir, in other Pompe aqueous composition will be provided in a flexible container such as a tank, which is wholly or mainly made of a material other than glass such as plastic.
For many aqueous compositions is extremely difficult to find a non-glass material which can safely be used to store said aqueous composition before its use by the patient. One of the many difficulties lies in the high mobility of the preservatives in the welded layer made of polymers such as polyethylene (herein designated PE), polypropylene (herein designated PP), polyethylene terephthalate (herein designated PET) or the like, in combination with high affinity preservatives to the widely used adhesives for polyurethane used for weld bonding layer with moisture-resistant materials like polihlortriftoretilenu (herein referred PCTFE). Test results of the prior art plastic products containing a drug solution with preservatives, indicate that there is a rapid and undesirable decrease of the preservative in the drug solution. The main objective of the present inventors was to find a material or combination of materials that can be used to produce a transparent flexible container that meets the safety requirements for storage of pharmaceutical solutions containing a preservative such as phenol, m-cresol and benzyl alcohol. It was extremely difficult to find a material that meets these requirements.
Briefly, the object of the present invention to overcome or decrease in at least some of the disadvantages of the prior art.
A more specific object of the invention is to provide a container or tank.
Another object of the invention is to provide a flexible container.
Another object of the invention is to provide a transparent container.
Another object of the invention is to provide a container that allows for sterilization.
Another object of the invention is to provide materials which can be welded to form the aforementioned tank.
Another object of this invention is to provide a container which can be used for storage of liquid solutions or suspensions of drugs, which may contain preservatives.
Another object of the invention is to provide a container which has a sufficient transparency to allow inspection of the container contents.
Another object of the invention is to provide a container which can be used for storage of liquid solutions or suspensions of drugs, optionally containing preservatives and which is not, or only to a minimal degree consists of glass.
Another object of the invention is to provide a container having barrier properties ensuring that the concentration of active ingredient in the aqueous composition is not changed substantially during storage for a sufficient period of time.
Another object of the invention is to provide a container having barrier properties ensuring that the concentration of any preservative present in the aqueous composition is not changed substantially during storage for a sufficient period of time.
Another object of the invention is to provide a container which can be tightly welded with a suitable septum material.
Another object of the invention is to provide a container which can be tightly glued with a suitable septum material by other means than welding.
Another object of the invention to provide a film package which can be used for storing a medicament by sterile water.
Another object of the invention is to provide a package which can be used as a reservoir for the pump, and preferably, said reservoir contains a drug to an aqueous-based.
Another object of the invention is to provide a film material for said package which satisfy certain functional requirements such as physical properties of the material after sterilization, chemical requirements for the material after sterilization, and cleanliness.
Thus, one object of the invention is to provide a film material for said package which can be sterilized, for example using gamma radiation, electron beam, steam, or ethylene oxide.
Another object of the invention is to provide a film material for said packet, which, after sterilization, fulfills most of or all the following physical requirements: 1) the material must be transparent; 2) the material must provide a good barrier against water; 3) the material must provide a good barrier against gases (e.g., oxygen and carbon dioxide); 4) the material must provide a good barrier against preservatives (for example, phenol and meta-cresol); 5) the material must provide a good barrier against odors (for example preservatives); 6) the material must be resistant to fracture stress loads the environment (for example, oils, perfumes); 7) the material must be resistant to cracking during bending; 8) the material must have good sealing properties (for example, by welding); 9) the material must not delaminate after sterilization, during processing or storage, and 10) the material must not undergo significant relaxation during storage and use.
Another object of the invention is to provide a film material for said packet, which, after sterilization, fulfills most of or all the following chemical requirements: 1) the material must not release a drug substance, which may affect the health and safety of the patient (leachables); 2) the material must have a very low level of extractables and 3) the material must be compatible with the drug.
Another object of the invention is to provide a film material for said packet, which, after sterilization satisfies the following requirements for cleanliness: 1) it must be possible to manufacture the material of hygienic conditions and 2) the final product must be free of dust and particles.
Another object of the present invention is to provide a film material for said package which satisfies certain health and safety requirements, preferably most of the requirements mentioned in 1) European Pharmacopoeia (Ph. Eur.) 2002, 4th edition; 2) The United States Pharmacopeia (USP) 25; 3) Japanese Pharmacopeia (JP) XIV; 4) Directive 90/128 EEC + amendments (EEC Directive 90/128 + amendments) "Relating to plastics materials and articles intended to come into contact with foodstuffs"; 5) United States Code of Federal Regulations (CFR), Chapter 21, Food and Drug Administration, part of the 170-190; 6) III / 9090/90 EN. Plastic Primary Packaging Materials. Note for Guidance and 7) Guidance for Industry. Container Closure Systems for Packaging Human Drugs and Biologies, Chemistry, Manufacturing, and Controls Documentation. FDA, May 1999.
Definitions
Coextrusion is a process whereby two or more than two polymer materials are melted in two or more than two extruders and extruded together through a flat slit or slits system planar and cooled to obtain a coextruded polymer film.
Extrusion-lamination (also designated as coextrusion lamination) is a process in which raw materials in the form of a polymer film of one material is coated through a flat slit or system planar slits of one or more than one extruder, a single layer or more than one layer of melted material or materials and then cooled to form the extrusion-laminated resin film.
Lamination is a process in which the two source material polymer film bonded together by the addition of an appropriate adhesive to a polymer film followed by the second polymeric overlay film to form a laminated polymeric film.
The tie layer is a layer which is sandwiched between two resin layers to provide a compound of these two layers together.
The term "container", which is herein also means a package or reservoir, is a product which may contain a liquid. This container is made of film or sheet material.
The inner layer of the chamber of said container is in direct contact with the liquid that is to be stored in said container.
"The outer layer of the chamber of the container" is a layer that is not in direct contact with the liquid that is to be stored in said container. In other words, the inner layer located between said outer layer and said liquid. With respect to the layers, the terms "inner" and "outer" refer to the position of the two layers relative to each other, and determines the position of the fluid from the inner to the outer. For example, this terminology does not contradict the fact that the next layer can be adhered to the outer layer with its outer side, whereby in fact the so-called outer layer is placed between, on the one hand, the so-called inner layer and, on the other hand, the additional layer adhered to the so-called outer layer with its outer side.
Flexible object is an object that can bend and flex easily and which does not break (it is not bent too much). Glass is not flexible. Here, the term "flexible" in connection with the containers indicates that if the container is subjected to a force, for example by filling it with liquid, it will change its form without breaking.
Here, the term "insulin" refers to any type of insulin such as porcine insulin, bovine insulin, and human insulin and salts thereof such as salts and protamine zinc salts, as well as active derivatives of insulin and insulin analogs. The term "active derivatives of insulin" means that one skilled in the art is usually regarded as derivatives cm. Number of general books, for example, insulin having a substituent not present in the parent insulin molecule. The term "insulin analogs" refers to insulin wherein one or more amino acid residues is replaced by another amino acid residue and / or from which one or more amino acid residues deleted, and / or wherein one or more of the amino acid residues are added, with the proviso that said insulin analogue has a sufficient insulin activity. Using the results of the analysis of the so-called free fat cell, one skilled in the art, such as a physician, knows when and in what dosages administered insulin analog. Examples of insulin analogues are described in the following patents and equivalents: US 5618913, EP 254516, EP 280 534, US 5750497 and US 6011007. Examples of specific insulin analogues are insulin aspart (human insulin wherein the amino acid proline at position B28 is substituted with aspartic acid AspB28 ), insulin lispro (human insulin, wherein the substituents are LysB28, ProB29) and insulin glargine (human insulin, wherein the substituents are GlyA21, ArgB31, ArgB32). Here, the term "insulin" also covers compounds which can be considered as derivatives of insulin and insulin analogues. Examples of such compounds are described in patents US 5750497 and US 6011007 and their equivalents. An example of particular analogs and derivatives of insulin is insulin detemir (ie des-ThrB30 human insulin γ LysB29 -tetradecanoyl).
The term "U", a hen used herein, refers to insulin units. Most currently used (commercially available) insulins (bovine, porcine, human, lispro, aspart, and glargine) is effective in a single unit, which is equivalent to 6 nmol. Long-acting insulins have reduced efficacy relative to human insulin. Thus, for insulin detemir one unit corresponds to 24 nmol. For other insulins relation between U and nmol can be determined, if not already known, for example, by determining the amount giving a pharmacological effect (reduction of blood glucose), human insulin-like effect.
SUMMARY OF THE INVENTION
Briefly, the present invention relates to a flexible transparent watertight container composed of a film comprising two layers, an inner layer and an outer layer, which are joined together to form a film, and this film is shaped transparent packet which has sufficient moisture resistance, resistance to phenol and meta cresol, allowing long term storage of a solution or suspension of the drug containing water, phenol and / or m-cresol without significant changes in concentration of water, phenol and meta-cresol for a long period of time, and which can be sterilized by irradiation.
In another aspect, the present invention relates to a method for storing a liquid solution and / or suspension of insulin for a significant period of time for use in the delivery device, comprising the steps of formation of a stack of the transparent plastic film that is sufficiently water resistant, resistant to phenol and meta-cresol which allows storage of insulin for two years without degradation of its pharmaceutical properties; sterilization of the package and the premises of the insulin compounds inside this storage bag for a considerable period of time.
BRIEF DESCRIPTION OF THE DRAWINGS
1 and 2 are examples of embodiments of this invention.
Figure 1 shows a cross section through the wall of the chamber in the container of the present invention. The inner layer 2 is in direct contact with liquid stored in said container. Typically, the outer layer 1 (which may be a PCTFE layer) is not in contact with the liquid in the container. In this embodiment of the invention shown in Figure 1, the inner and outer layers are bonded together using the binder layer 3.
Figure 2 is identical to Figure 1, but in Figure 2 of Figure 1 are replaced by numbers corresponding explanatory text.
3 shows one side of the flexible container. The welded area 4 shown in this figure, provides sealing of the container. The inner part 5 of the container can be filled with liquid.
4 shows a sectional view along line 1-1 in Figure 3, arranged perpendicular to the surface shown in Figure 3. The wall 6 of the container consists of an outer layer 1, the inner layer 2 and the binder layer 3.
Figure 5 shows a cross section through the container wall in a particular embodiment of the present invention and a portion placed in the container liquid.
DISCLOSURE OF PREFERRED EMBODIMENTS
It was surprisingly found that a container described in the claims below corresponds to the requirements for the container to be used for storage of aqueous, in particular drug solution containing preservatives such as phenol or meta-cresol.
In one aspect, this invention relates to a flexible, at least partially transparent container for storage of a liquid in a watertight chamber, the wall material of which comprises at least two layers, an inner layer which is in direct contact with said liquid when said chamber contains a liquid, and an outer layer which is not in contact or are only minimally or to the lowest degree in contact with said liquid when said chamber contains a liquid, wherein said inner and outer layers are inseparably connected together, characterized in that the chamber is filled with water and its storage at a temperature of about 5 ° C for 24 months less than 10 wt.% of water diffuses out of the container and the chamber is filled with water containing about 1.8 mg / ml (19 mmol) of phenol, and its storage at approximately 5 ° C. 24 months, the change in concentration of phenol in the liquid is less than about 10 wt.%.
In another aspect, this invention relates to a flexible, at least partially transparent container for storage of a liquid in a watertight chamber, the wall material of which comprises at least two layers, an inner layer which is in direct contact with said liquid when the chamber contains a fluid and an outer layer which is not in contact or are only minimally or to the lowest degree in contact with said liquid when the chamber contains a fluid, wherein said inner and outer layers are inseparably connected together, characterized in that the chamber is filled with water and its storage at about 5 ° C for 24 months less than 10 wt.% of water diffuses out of the container and the chamber is filled with water containing about 1.8 mg / ml (19 mmol) of phenol, and its storage at a temperature of about 37 ° C for 12 weeks change in the concentration of phenol in the liquid is less than about 10 wt.%.
In a preferred embodiment, the outer layer of the chamber of the container is designed in such a way that it ensures compliance requirements, when filling the chamber with water, and its storage at about 5 ° C for 24 months less than 10 wt.%, Preferably less than 5 wt.% , more preferably less than 3 wt.% of water diffuses out of the container.
In another preferred embodiment, the inner layer of the chamber of the container is designed in such a way that it ensures compliance requirements, when filling the chamber with water containing about 1.8 mg / ml (19 mmol) of phenol, and its storage at approximately 5 ° C. 24 months, the change in concentration of phenol in the liquid is less than about 10 wt.%, or when the chamber is filled with water containing about 1.8 mg / ml (19 mmol) of phenol, and its storage at a temperature of about 37 ° C for 12 weeks, the change concentration of phenol in the liquid is less than about 10 wt.%.
According to another preferred embodiment, the inner layer of the chamber of the container described above is welded.
According to another preferred embodiment, the inner layer of the chamber of container described above has a thickness of greater than about 10 microns, preferably greater than about 20 microns, and less than about 60 microns, preferably less than about 50 microns, more preferably less than about 40 microns.
According to another preferred embodiment of the invention relates to a container as described above, from which when filled with water and when stored at a temperature of about 5 ° C for 24 months diffuses less than 10 wt.%, Preferably less than 5 wt.%, More preferably less than 2 wt .% water.
According to another preferred embodiment of the invention relates to a container as described above, which when filled with water containing about 1.8 mg / ml (19 mM) of phenol and stored at a temperature of about 5 ° C for 24 months, the change in concentration of phenol is less than about 10 wt.%, preferably less than about 5 wt.%, more preferably less than about 2 wt.%.
According to another preferred embodiment of the invention relates to a container as described above, which when filled with water containing about 1.8 mg / ml (19 mM) of phenol and stored at a temperature of about 37 ° C for 12 weeks, the change in concentration of phenol is less than about 10 wt.%, preferably less than about 5 wt.%, more preferably less than about 2 wt.%.
According to another preferred embodiment of the invention relates to a container as described above, which when filled with water containing about 2.06 mg / mL (19 mM) of m-cresol and stored at a temperature of about 5 ° C for 24 months, the change in concentration meta-cresol is less than about 10 wt.%, preferably less than about 5 wt.%, more preferably less than about 2 wt.%.
According to another preferred embodiment of the invention relates to a container as described above, which when filled with water containing about 2.06 mg / mL (19 mM) of m-cresol and stored at a temperature of about 37 ° C for 12 weeks, the change in concentration meta-cresol is less than about 10 wt.%, preferably less than about 5 wt.%, more preferably less than about 2 wt.%.
According to another preferred embodiment of this invention, it relates to a container as described above, which is manufactured from a batch of polymer film, which when tested as described in Test A below gives a maximum loss of m-cresol of about 10%, preferably not more than about 5%.
According to another preferred embodiment of this invention, it relates to a container as described above, which is manufactured from a batch of polymer film, which when tested as described in Test A below gives a change in pH, which is approximately +/- 0.2.
According to another preferred embodiment of this invention, it relates to a container as described above, which is manufactured from a batch of polymer film, which when tested as described in Test B below gives a maximum weight loss of about 2.5%, preferably not more than about 1%.
According to another preferred embodiment of this invention, it relates to a container as described above, which is manufactured from a batch of polymer film, which when tested as described in Test B below gives a maximum loss of m-cresol of about 10%, preferably not more than about 5%.
According to another preferred embodiment of this invention, it relates to a container as described above, which is manufactured from a batch of polymer film, which when tested as described in Test B below gives a change in the pH value which is about +/- 0.2.
According to another preferred embodiment of this invention, it relates to a container as described above, which is manufactured from a batch of polymer film, which when tested as described in Test C below gives a maximum weight loss of about 2.5%, preferably not more than about 2%.
According to another preferred embodiment of this invention, it relates to a container as described above, which is manufactured from a batch of polymer film, which when tested as described in test C below gives a maximum loss of m-cresol of about 10%, preferably not more than about 5%.
According to another preferred embodiment of this invention, it relates to a container as described above, which is manufactured from a batch of polymer film, which when tested as described below to test C gives a maximum loss of phenol of about 10%, preferably not more than about 5%.
According to another preferred embodiment of this invention, it relates to a container as described above, which is manufactured from a batch of polymer film, which when tested as described below to test C gives a change in the pH value which is about +/- 0.2.
According to another preferred embodiment of this invention, it relates to a container as described above, which is manufactured from a batch of polymer film that meets test D described below for the dilution 1:50, preferably dilution 1: 100, more preferably dilution 1: 200, even more preferably to 1: 400 dilution.
According to another preferred embodiment of this invention, it relates to a container as described above, which is flexible.
According to another preferred embodiment of this invention, it relates to a container as described above, which is equipped with a device whereby said liquid can be ejected from said container.
According to another preferred embodiment of this invention, it relates to a container as described above, which comprises an additional third polymer layer on the outer side of the PCTFE layer.
According to another preferred embodiment of this invention, it relates to a container as described above, which, when completely filled with liquid, can contain an amount of liquid that is at least about 0.5 ml, preferably at least about 1 ml, and not more than about 10 ml, preferably no more than about 5 ml, more preferably not more than about 2 ml, and most preferably the volume is approximately 1.5 ml. According to a particular preferred embodiment of this invention, it relates to a container containing from about 2 ml to about 4 ml, preferably 3 ml.
According to another preferred embodiment of this invention, it relates to a container as described above which is partially or completely filled with the liquid pharmaceutical composition.
According to another preferred embodiment of this invention, it relates to a container as described above, wherein at least 95% by volume, preferably at least 98 volume%, more preferably at least 99% by volume and even more preferably at least 99.9% by volume the inner portion of the container contains the liquid pharmaceutical composition.
According to another preferred embodiment of this invention, it relates to a container as described above which is partially or completely filled with a liquid pharmaceutical composition wherein the active ingredient is a peptide.
According to another preferred embodiment of this invention, it relates to a container as described above which is partially or completely filled with a liquid pharmaceutical composition wherein the active ingredient is insulin.
According to another preferred embodiment of this invention, it relates to a container as described above, wherein the content of insulin in said container is in the range from about 10 U / ml to about 1500 U / ml.
According to another preferred embodiment of this invention, it relates to a container as described above, containing a solution or suspension, which contain a preservative.
According to another preferred embodiment of this invention, it relates to a container as described above which is partially or completely filled with a liquid pharmaceutical composition containing phenol.
According to another preferred embodiment of this invention, it relates to a container as described above which is partially or completely filled with a liquid pharmaceutical composition containing m-cresol.
According to another preferred embodiment of this invention, it relates to a container as described above which is partially or completely filled with a liquid pharmaceutical composition containing benzyl alcohol.
In another aspect, this invention relates to the use of the container as described above for storing a liquid pharmaceutical composition as mentioned above.
In yet another aspect, this invention relates to a container for storing the liquid in a watertight chamber, wherein the wall material of the chambers comprises at least two layers wherein the inner layer is in direct contact with said liquid when said chamber contains a liquid, and another layer consisting of PCTFE film is not or is only minimally or to the lowest degree in contact with said liquid when said chamber contains a liquid, said inner layer consists of PE or PP film, and either said inner layer and said PCTFE layer are The extrudate or coextrudate-laminate or said inner layer and said PCTFE layer joined together, and the thickness of said PCTFE layer is greater than about 40 microns and less than about 100 microns, preferably less than about 75 microns.
According to a preferred embodiment of this invention, it relates to a container as described above, which is at least partially transparent.
According to a preferred embodiment of this invention, it relates to a container as described above, which is totally transparent.
The inner layer of the container of the present invention may consist of polyethylene (herein designated PE) or polypropylene (herein designated PP) or mixtures of PE and PP. PE consists of at least 75 wt.%, Preferably at least 90 wt.%, More preferably at least 95 wt.% Polyethylene. PP consists of at least 75 wt.%, Preferably at least 90 wt.%, More preferably at least 95 wt.% Polypropylene.
In a preferred embodiment of the invention, PE is as defined in the European Pharmacopoeia 2001, 4th Edition, point 3.1.5, the content of which is incorporated herein by reference. Examples of components present in PE are higher alkene homologues (C3-C10) and other additives mentioned therein.
In a preferred embodiment of the invention, PP is as defined in the European Pharmacopoeia 2001, 4th Edition, point 3.1.6, the content of which is incorporated herein by reference. Briefly, PP consists of the homopolymer of propylene or a copolymer of propylene with not more than 25% of ethylene or a mixture (alloy) of polypropylene with not more than 25% of polyethylene. It may contain additives, see para. 3.1.6 above.
In a preferred embodiment of the invention, the inner layer is a PCTFE layer consisting of at least 75%, preferably at least 90%, more preferably at least 95 wt.% Polihlortriftoretilenovoy film, for example, Aclar® from Honeywell, Morris Town , New Jersey, USA.
In another preferred embodiment of the invention, the outer layer is a PCTFE layer consisting of at least 75 wt.%, Preferably at least 90 wt.%, More preferably at least 95 wt.% Polihlortriftoretilenovoy film, for example, Aclar® from Honeywell, Morris Town, New Jersey, USA.
Adhesive which can be used for the inner and outer layers, such as PCTFE layer, are joined together may consist of an adhesive, for example polyethyleneimine (hereinafter designated PEI) or any other suitable tie layer. Alternatively, the bonding layer can be a polyolefin having at least one functional group of an unsaturated carboxylic acid or its anhydride. Alternatively, the bonding layer can be a polyolefin having at least one functional group of an unsaturated carboxylic acid or its anhydride. Examples are: Lotader, Lotryl, Evatane and Orevac, e.g., ATOFINA, Lavamelt, for example, BAYER, PROVISTA and EASTAR, e.g., EASTMAN, Bynel, for example, DuPont, AMPLIFY and INTEGRAL, e.g., Dow.
Further examples of tie layers are mentioned in WO 98/25762, the contents of which are incorporated herein by reference. As an example, a specific binder layer can also be made to the one used in Aclar® CX 130 from Honeywell.
It is important to select a binder layer that is not affected in any undesired manner to the finished material. In a preferred embodiment of the invention the bonding layer is such that only very low amounts of phenol, m-cresol or benzyl alcohol disappears for a period of 24 months at 5 ° C or for a period of 12 weeks at 27 ° C when an aqueous solution containing about 1.8 mg / ml of phenol is placed in a container according to the present invention, see. the tests described below.
Known tie layers have a thickness of, for example 2 or 8 um. According to a preferred embodiment of this invention, it relates to a container as described above, wherein the tie layer or tie layers in the polymer film have a thickness ranging from about 1 micron to about 10 microns, preferably less than about 8 microns, more preferably less than about 6 microns.
For the manufacture of containers according to the present invention, the use of coextruded-laminated products is not limited to some of the specific polymer layers mentioned above such as PP or PE and PCTFE.
An example of coextruded-laminated product not made of PP or PE and PCTFE is co-extruded polymeric film of PE-PET laminated to PCTFE which can be prepared by use of standard lamination techniques known in the art. This structure has a significant barrier against mobile molecules like m-cresol.
The third polymer layer may be deposited on the outer side of the outer layer, for example on the outer side PCTFE layer. Examples of such a third layer are PP, PE, PET-G (polietilentereptatglitserin modified), and TPE (thermoplastic elastomer), which enable the welding to the outer side of the tank. 5 shows an example where the use of such a third polymeric layer. In this example, an additional layer may be the same or different than the inner layer. In a preferred embodiment of the invention, the additional layer and the inner layer are identical or almost identical.
In a preferred embodiment of the invention, the thickness of the inner layer is at least about 20 microns, preferably at least about 30 microns, and no more than about 100 microns, preferably not more than about 75 microns.
The polymer film to make the container of this invention consisting of a coextrudate may be prepared as described below.
Raw PCTFE (pellets or powder), a binder raw material and raw materials PE layer is melted in three separate extruders and soekstruziruyut in a molten state through a flat slit preferred thickness and cooled and then formed into a polymer film.
The polymer film to make the container of this invention consisting of an extrudate-laminate may be made as described below.
Raw polymer film PCTFE preferred thickness is treated by a process of extrusion-lamination wherein molten tie layer that acts as a sealant, is added to a polymer film followed by addition PCTFE molten welding layer such as PE, PP or any other polymer. The extrudate-laminate is cooled on a cooling drum or the like and is vented. The chemical nature of the bonding layer is such that it has a low affinity to aromatic preservatives like m-cresol and phenol.
The polymeric film usable for manufacturing the container of this invention consisting of a laminate may be made as described below.
Another useful method for manufacturing a laminate is to use a raw material of the polymer film a preferred thickness of the PCTFE in combination with a binder, followed by lamination to polymeric film are preferred welding layer, e.g., coextruded PET-PE preferred thickness. The basis of the binder usually is a polyurethane having a low affinity to aromatic preservatives like m-cresol and phenol.
The container of the present invention, where two layers are joined together by welding, may be made as described below.
Weldable layers superposed on each other and welded together by using any suitable welding technique known in the art, for example by heat, ultrasound, laser or the like. The outer and inner periphery of the weld zone is determined taking into account the size and shape of the tank.
The container of this invention should have a flexibility which allows filling the container so that it can be used as the package.
If the aqueous composition contains a preservative it is important that its concentration was sufficient to maintain antimicrobial efficacy.
In a preferred embodiment, the container of this invention consists of a material which enables sterilization container suitable manner such as β- or γ-irradiation or by heating.
In a preferred embodiment, the container of this invention consists of a material which satisfy the following tests are flexible.
Two rectangular pieces of the material being tested both having the size 60 mm × 20 mm are welded together with a 3 mm welding zone forming a welded test package and then the package is filled with 1.5 ml of water. If the overpressure is below 100 mbar, the material is sufficiently flexible.
In a preferred embodiment of the invention, the container of the present invention to be used for storage of an aqueous pharmaceutical composition, for example a solution or suspension of a pharmaceutically active compound.
In a preferred embodiment of the invention, the active ingredient in said pharmaceutical composition is a protein. In a further preferred embodiment of the invention, the active ingredient is insulin, growth hormone or factor VII and analogs thereof. In a preferred embodiment of this invention, the amount of insulin in aqueous solution or suspension is in the range with a lower limit of about 10 U / ml, preferably about 40 U / ml, more preferably about 100 U / ml, and even more preferably about 150 U / ml, and an upper limit of about 1500 U / ml, preferably about 1000 U / ml, more preferably about 500 U / ml, most preferably about 300 U / ml.
In a preferred embodiment of the invention, the aqueous formulation contains a stabilizer. In a more preferred embodiment of this invention, the aqueous formulation contains phenol. In another preferred embodiment of the invention, the aqueous formulation contains m-cresol. In another preferred embodiment of the invention, the aqueous formulation contains benzyl alcohol. In a further preferred embodiment of the invention, the total concentration of phenol and / or m-cresol in the aqueous formulation is in the range from about 20 mM to about 50 mM, preferably from about 30 mM to about 45 mM. The concentration of phenol and / or m-cresol, among others depends on the concentration of insulin in the aqueous formulation. In a preferred embodiment of this invention, the amount of phenol in the aqueous solution is in the range of from about 15 to about 25 mM. In another preferred embodiment of this invention, the amount of meta-cresol in the aqueous solution is in the range of from about 15 to about 25 mM. In another preferred embodiment of this invention, the amount of benzyl alcohol in the aqueous formulation is in the range of from about 15 to about 25 mM. In another preferred embodiment of this invention, benzyl alcohol in the aqueous formulation is absent.
When selecting materials to be used for manufacturing the container of the present invention, it is important to select materials which do not absorb too much of the active ingredient, and other ingredients present in the aqueous pharmaceutical composition.
As indicated in the claims below, the container of the present invention may be equipped with a device whereby said liquid can be ejected from said container (when desired). An example of such a device may be a needle penetration septum, made of a rubber material adhered to the inner or outer side of the polymer film of the container or in the welding zone between the two polymer films. Another example can be an active or a passive closure valve adhered to the container. The container of the present invention may be emptied by application of external pressure to the reservoir or by suction from a pump device.
The container of the present invention can be used in many applications, such as the pump, syringe or syringe type of pencil. Conveniently, the container of the present invention was disposable.
The present invention also relates to a film material comprising at least two layers, wherein said layers are inseparably connected together, which can be used for the manufacture of a transparent container according to the present invention. In a preferred embodiment of the present invention film material may be used directly for the manufacture of containers claimed herein. For example, the film material of the invention does not need to process to fully attach additional film to one of the two surfaces.
Mention here does not allow links that they constitute prior art.
The word "comprise" is to be interpreted broadly meaning "include", "contain" or "comprise" (see. Guidelines for Examination in the European Patent Office 2000, part C, chapter III, 4.13).
Testing Methods
In a preferred embodiment of the container of the invention is made of a packet of polymer films that satisfy all or some of the following tests.
Test A
Test for loss of m-cresol and pH change
First, a stack of flat sheets of A4 polymeric film with a total thickness less than 1 cm is irradiated with an electron beam 2 × 25 kHz.
Then, 10 cm2 (2 × 5 cm 2) of polymer film 15 is cut into smaller pieces (1 × 0.7 cm 2) and immersed in 1.5 ml of a solution containing about 1.80 mg / mL (19 mM) phenol, 2, 06 mg / ml (19 mmol) of m-cresol, 16.0 mg / mL (174 mM) glycerol, 1.25 mg / mL (7 mM) disodium hydrogen phosphate solution, 0.58 mg / mL (10 mM) sodium chloride and pH 7.40. Immersed sample and reference sample are placed in an incubator at 37 ° C for 1 week.
The content of meta-cresol in the solution was analyzed by using a chromatographic method.
This test must show the total migration of meta-cresol including the absorption directly into the adhesive layer on the edge. When stored at the above conditions must meet the following requirements: the maximum loss of m-cresol should be 10%, and preferably the loss of less than 5%. The pH of the solution should not change more than +/- 0.2.
Test B
Test for permeability, loss of m-cresol and pH
The modified test "Paddington Cup" (DS / EN 13726-2 as amended).
The test polymer film is placed between two flanges, so that the inner 10 cm2 plastic film (PE, PP or any other welding layer) in contact with 5 ml of a solution with a pH of 7.40, containing about 1.80 mg / mL (19 mM) phenol, 2.06 mg / ml (19 mmol) of m-cresol, 16.0 mg / mL (174 mM) glycerol, 1.25 mg / mL (7 mM) disodium hydrogen phosphate solution, 0.58 mg / ml (10 mmol) of sodium chloride. Paddington cup is placed upside down allowing direct contact between the solution and the polymer film in an incubator at 37 ° C and a maximum relative humidity of 15% for 1 week in parallel with the comparison sample, wherein use Paddington cup with an inert aluminum foil. Paddington cups are weighed before and after incubation. The content of meta-cresol is analyzed by using a chromatographic method. This test is useful to test the total evaporation and should show the barrier properties against preservatives like m-cresol and phenol. When stored at the above conditions, the following requirement should be fulfilled: The maximum weight loss should be 2.5%, preferably less than 1%, the maximum loss of m-cresol should be 10%, and preferably less than 5%, and the pH value should not change more than by +/- 0.2.
Test C
Test packets carrier
In this test packages made by welding plastic sheets and filling them with a carrier. Several packages are weighed before storage at 37 ° C and 15% relative humidity and then weighed, for 12 weeks. Several packages were stored at 37 ° C and tested for content of m-cresol and phenol at regular intervals for 12 weeks. Glass vials are used as comparative samples. When stored at the above conditions for 12 weeks must meet the following requirements: the maximum weight loss is 2.5%, preferably less than 1%, the maximum loss of m-cresol should be 10%, and preferably less than 5%, the maximum loss of phenol should equal to 10% and preferably less than 5%, and the pH value should not change more than +/- 0.2.
Test D
Transparency filled package
Filled package must meet the transparency requirements of the European Pharmacopoeia 2001, 4th edition, part 3.2.2.1, relating to plastic containers for aqueous solutions for parenteral infusion. For this method, the solution S is diluted 1: 200 (for PE or PP) or 1: 400 for other containers. This test can be modified by testing solution S, diluted 1:50 or 1: 100.
The following examples are offered to illustrate but not limit the scope of the invention.
EMBODIMENTS
EXAMPLE 1
Polychlorotrifluoroethylene (50 micron) coextruded with polyethyleneimine modified epoxy (bonding layer) and polyethylene (50 micron). This coextruded polymer film used to make the container with a volume of approximately 1.5 ml by heat welding.
EXAMPLE 2
Coextrudate PE-PET is laminated using a polyurethane-based adhesive for laminating Aclar® UltrR × 2000 and PET, to obtain a structure like PE-PET / Aclar® UltrR × 2000 / PET, where "/" indicates the use of adhesives. This coextruded polymer film used to make the container with a volume of approximately 1.5 ml by heat welding.
EXAMPLE 3
Polypropylene (50 micron) was laminated on the PCTFE layer of a polymer film made in Example 1. The polymer film consisting of 3 polymers will be useful for the manufacture of packets using the PE welding layer that will allow bonding member consisting of a material which allows to carry out welding with PP layer on the outside of the package.
EXAMPLE 4
Experimental multilayer film composed of polyethylene (25 microns) and PCTFE (50 microns) with a binder layer obtained according to PCT / BE 03/000226 applicant Tekni-Plex Europe NV, which signed an agreement on confidentiality, were tested by the above-mentioned test A, B and C. The results of these tests were as follows:
Test A: The loss of m-cresol was 1%. The pH was changed from 7.43 to 7.35.
Test B: The loss of m-cresol was 1%. The weight loss was 0.1%.
Test C: The weight loss was 1.3%. The loss of m-cresol was 8.7%. The loss of phenol was 2.1%. The pH value changed from 7.35 to 7.20 for drug product.
Contents10
Every citation, both ways
| Document | Relation | Office |
|---|---|---|
| EP1033326A | Cites | European Patent Office (EPO) |
| US2003008152A1 | Cites | United States of America |
| US3403064A | Cites | United States of America |
| RU2291681C2 | Cites | Russian Federation |
| RU2208517C2 | Cites | Russian Federation |
| RU2300365C2 | Cites | Russian Federation |
20 members in 13 offices
Priority claims40
| Document | Office | Kind | Date |
|---|---|---|---|
| PA200300971 | Denmark | – | |
| PA200300971 | Denmark | A | |
| PA200300971 | Denmark | A | |
| 50471503 | United States of America | P | |
| 50471503 | United States of America | P | |
| 60504715 | United States of America | – | |
| 52334903 | United States of America | P | |
| 52334903 | United States of America | P | |
| 60523349 | United States of America | – | |
| PA200301717 | Denmark | – | |
| PA200301717 | Denmark | A | |
| PA200301717 | Denmark | A | |
| 52479303 | United States of America | P | |
| 52479303 | United States of America | P | |
| 60524793 | United States of America | – | |
| PA200301741 | Denmark | – | |
| PA200301741 | Denmark | A | |
| PA200301741 | Denmark | A | |
| 52546903 | United States of America | P | |
| 52546903 | United States of America | P | |
| 60525469 | United States of America | – | |
| PA200301746 | Denmark | – | |
| PA200301746 | Denmark | A | |
| PA200301746 | Denmark | A | |
| 2004000440 | Denmark | W | |
| 2004000440 | Denmark | W | |
| 60504715 | – | – | – |
| 60523349 | – | – | – |
| 60524793 | – | – | – |
| DKPA200300971 | – | – | – |
| DKPA200301717 | – | – | – |
| DKPA200301741 | – | – | – |
| DKPA200301746 | – | – | – |
| PA200300971 | – | – | – |
| PA200301746 | – | – | – |
| US20030504715P | – | – | – |
| US20030523349P | – | – | – |
| US20030524793P | – | – | – |
| US20030525469P | – | – | – |
| WO2004DK00440 | – | – | – |
Members20
| Document | Office | Kind | |
|---|---|---|---|
| AU2004251810A1 | Australia | A1 | |
| CA2529023A1 | Canada | A1 | |
| WO2005000580A1 | World Intellectual Property Organization (WIPO) | A1 | |
| KR20060029154A | Republic of Korea | A | |
| EP1641616A1 | European Patent Office (EPO) | A1 | |
| CN1791511A | China | A | |
| US2006134358A1 | United States of America | A1 | |
| RU2005139050A | Russian Federation | A | |
| ZA200508683B | South Africa | B | |
| JP2007506464A | Japan | A | |
| RU2381103C2This record | Russian Federation | C2 | |
| AU2004251810B2 | Australia | B2 | |
| EP2301749A1 | European Patent Office (EPO) | A1 | |
| EP1641616B1 | European Patent Office (EPO) | B1 | |
| AT505323T | Austria | T | |
| ATE505323T1 | Austria | T1 | |
| DE602004032237D1 | Germany | D1 | |
| JP4781264B2 | Japan | B2 | |
| PL1641616T3 | Poland | T3 | |
| US8399078B2 | United States of America | B2 |
1 legal event, as the office reported them to INPADOC
Events
| Event | Code | |
|---|---|---|
| The patent is invalid due to non-payment of feesMM4A | MM4A |
Numbers
- Publication
- 2381103
- Publication, DOCDB
- 2381103
- Publication, EPODOC
- RU2381103
- Application
- 200513905004
- Application, DOCDB
- 2005139050
- Application, EPODOC
- RU20050139050
Titles2
- Russian
- КОНТЕЙНЕР ДЛЯ ЖИДКИХ ФАРМАЦЕВТИЧЕСКИХ КОМПОЗИЦИЙ С ВЫСОКИМИ ВЛАГОЗАЩИТНЫМИ СВОЙСТВАМИ
- English
- CONTAINER FOR LIQUID PHARMACEUTICAL COMPOSITIONS WITH HIGH MOISTUREPROOF PROPERTIES
Classification
- CPC, 17
- B32B27/08
- A61J1/00
- A61J1/10
- A61M2207/00
- B32B1/08
- B32B27/28
- B32B27/32
- Y10T428/1334
- Y10T428/1352
- B32B1/00
- B32B2323/10
- B32B2323/04
- B32B2439/80
- B32B2307/7246
- B32B27/304
- B32B2307/412
- B32B2327/12
- IPC, 10
- B32B27 08
- B65D30 08
- A61J1 10
- B32B27 06
- B32B27 30
- B32B27 32
- B32B27 36
- B65D30 14
- A61J1 00
- B32B1 00